Cognition Therapeutics Inc (CGTX) stock
CGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.63−0.01 (-1.39%)
Close on Nov 17, 2026Market cap $59.90MP/E –Yield –
Cognition Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Cognition Therapeutics's ebitda for the twelve months ending Dec 31, 2025 was -$47.76M. For fiscal 2025 it was -$47.76M. The highest annual figure on record is -$17.31M in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$47.76M | – |
| FY2024 | Dec 31, 2024 | -$53.86M | – |
| FY2023 | Dec 31, 2023 | -$50.63M | – |
| FY2022 | Dec 31, 2022 | -$43.47M | – |
| FY2021 | Dec 31, 2021 | -$28.51M | – |
| FY2020 | Dec 31, 2020 | -$17.31M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$13.66M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.36M | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.70M | – |
| Q3 FY2024 | Sep 30, 2024 | -$14.44M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.65M | – |
| Q1 FY2024 | Mar 31, 2024 | -$14.08M | – |
| Q4 FY2023 | Dec 31, 2023 | -$15.16M | – |
| Q3 FY2023 | Sep 30, 2023 | -$14.72M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.79M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.95M | – |
| Q4 FY2022 | Dec 31, 2022 | -$9.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.19M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.40M | – |
| Q4 FY2021 | Dec 31, 2021 | -$11.79M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$5.96M | – |
| Q1 FY2021 | Mar 31, 2021 | -$5.56M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.10M | – |
See a number that looks wrong?